Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia

AIDS. 2016 Jan;30(2):327-30. doi: 10.1097/QAD.0000000000000815.

Abstract

Residual immune activation was studied in 51 HIV-infected individuals, 16 with viral load between 1 and 20 copies/ml and 35 with viral load less than 1 copy/ml, and compared with results in 20 healthy blood donors. Higher T-cell activation and IP-10/CXCL10, MIG/CXCL9 and sCD14 plasma levels persisted in both HIV+ groups. The proportion of activated HLA-DR+ CD4 T cells was inversely correlated with the CD4 nadir and the current CD4 cell counts.

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active*
  • Blood Donors
  • CD4 Lymphocyte Count
  • Chemokines / blood
  • Cross-Sectional Studies
  • Female
  • HIV Infections / pathology*
  • HIV-1 / immunology*
  • HIV-1 / isolation & purification
  • HLA-DR Antigens / analysis
  • Humans
  • Lipopolysaccharide Receptors / blood
  • Lymphocyte Activation*
  • Male
  • Middle Aged
  • Viral Load
  • Viremia / drug therapy*

Substances

  • Anti-Retroviral Agents
  • Chemokines
  • HLA-DR Antigens
  • Lipopolysaccharide Receptors